NEW YORK (AP) -- CSL Ltd. and its unit CSL Biotherapies on Monday said it reached a marketing and distribution deal with drug developer Merck & Co. for the seasonal flu vaccine Afluria.
Financial details of the deal were not disclosed.
Australia-based CSL makes Afluria, which is sold in both pre-filled syringes and multi-dose vials. Under the deal, CSL has a six-year, exclusive marketing and distribution deal in the U.S.
Whitehouse Station, N.J.-based Merck will have exclusive sales and distribution rights in the U.S. beginning with the 2010-2011 flu season. CSL will retain the license.
Shares of Merck rose 30 cents to $31.55 in premarket trading.